• 1
    Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 10831084.
  • 2
    Hashimoto K, Tohyama M, Shiohara T. Drug reactions with eosinophlia and systemic symptoms (DRESS/DIHS). In: RevuzJ, RoujeauJC, KerdelFA, Vareyrie-AllanoreL, eds. Life-threatening Dermatoses and Emergencies in Dermatology. Verlag: Springer, 2009; 97102.
  • 3
    Tohyama M, Hashimoto K, Yasukawa M et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157: 934940.
  • 4
    Kano Y, Shiohara T. Sequential reactivation of herpesvirus in drug-induced hypersensitivity syndrome. Acta Derm Venereol 2004; 84: 484485.
  • 5
    Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006; 155: 301306.
  • 6
    Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006; 155: 344349.
  • 7
    Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J Dermatol 2005; 32: 278281.
  • 8
    Asano Y, Kagawa H, Kano Y, Shiohara T. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol 2009; 145: 10301036.
  • 9
    Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008; 144: 232235.
  • 10
    Viera MH, Perez OA, Patel JK, Jones I, Berman B. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS. Cutis 2010; 85: 312317.
  • 11
    Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56: 419425.
  • 12
    Picard D, Janela B, Descamps V et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2: 46ra62.
  • 13
    Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250257.
  • 14
    Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132136.
  • 15
    Cheng CC, Chang LY, Shao PL et al. Clinical manifestations and quantitative analysis of virus load in Taiwanese children with Epstein-Barr virus-associated infectious mononucleosis. J Microbiol Immunol Infect 2007; 40: 216221.
  • 16
    Hashizume H, Takigawa M. Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells. Acta Derm Venereol 2005; 85: 4750.
  • 17
    Jarrett RF, Clark DA, Josephs SF, Onions DE. Detection of human herpesvirus-6 DNA in peripheral blood and saliva. J Med Virol 1990; 32: 7376.
  • 18
    Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 1990; 335: 10471050.
  • 19
    Hashizume H, Aoshima M, Ito T, Seo N, Takigawa M, Yagi H. Emergence of circulating monomyeloid precursors predicts reactivation of human herpesvirus-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2009; 161: 486488.
  • 20
    Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40: 932940.
  • 21
    Yoshikawa T, Ihira M, Ohashi M et al. Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 7781.
  • 22
    Kitamura K, Asada H, Iida H et al. Relationships among human herpesvirus 6 reactivation, serum interleukin 10 levels, and rash/graft-versus-host disease after allogeneic stem cell transplantation. J Am Acad Dermatol 2008; 58: 802809.
  • 23
    Suga S, Yoshikawa T, Asano Y, Nakashima T, Kobayashi I, Yazaki T. Activation of human herpesvirus-6 in children with acute measles. J Med Virol 1992; 38: 278282.
  • 24
    Balachandra K, Chimabutra K, Supromajakr P et al. High rate of reactivation of human herpesvirus 6 in children with dengue hemorrhagic fever. J Infect Dis 1994; 170: 746748.
  • 25
    Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140: 183188.
  • 26
    Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 80718079.
  • 27
    Sugita K, Tohyama M, Watanabe H et al. Fluctuation of blood and skin plasmacytoid dendritic cells in drug-induced hypersensitivity syndrome. J Allergy Clin Immunol 2010; 126: 408410.
  • 28
    Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 18351837.
  • 29
    Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 12191226.